|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR-OOC-15006935 |
|
最近更新日期: Date of Last Refreshed on: |
2016-06-29 20:08:05 |
|
注册时间: Date of Registration: |
1990-01-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
一项针对基础胰岛素治疗标准化路径的糖尿病管理研究 |
|
Public title: |
Diabetes care management study focusing on standardized basal insulin treatment pathway |
|
注册题目简写: |
BEYOND II |
|
English Acronym: |
BEYOND II |
|
研究课题的正式科学名称: |
一项针对基础胰岛素治疗的糖尿病管理质量改善研究 |
|
Scientific title: |
Diabetes care management quality improvement study focusing on basal insulin treatment |
|
研究课题代号(代码): Study subject ID: |
LANTUL07189 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
赛诺菲 |
研究负责人: |
张彤 |
|
Applicant: |
Sanofi |
Study leader: |
ZHANG Tong |
|
申请注册联系人电话: Applicant telephone: |
+86 21 22266622 |
研究负责人电话:
Study leader's |
+86 10 65634801 |
|
申请注册联系人传真 : Applicant Fax: |
+86 21 60123538 |
研究负责人传真: Study leader's fax: |
+86 10 85215223 |
|
申请注册联系人电子邮件: Applicant E-mail: |
contact-us.cn@sanofi.com |
研究负责人电子邮件: Study leader's E-mail: |
tong3.zhang@sanofi.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区延安中路1228号静安嘉里中心办公楼3座19楼 |
研究负责人通讯地址: |
北京市朝阳区建国路108号海航实业大厦3层 |
|
Applicant address: |
19F Tower III, Kerry Center, 1228 Middle Yan'an Road, Jing'an District, Shanghai |
Study leader's address: |
3F, Haihang Building, 108 Jianguo Road, Chaoyang District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
200040 |
研究负责人邮政编码: Study leader's postcode: |
100022 |
|
申请人所在单位: |
赛诺菲(中国)投资有限公司上海分公司 |
||
|
Applicant's institution: |
SANOFI (CHINA) INVESTMENT CO., LTD. SHANGHAI BRANCH |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
中大附三医伦[2015]2-152号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
|
|
批准本研究的伦理委员会名称: |
中山大学附属第三医院临床医学研究伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Trial Ethic Committee of The Third Affiliated Hospital, Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2015-07-21 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中山大学附属第三医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Third Affiliated Hospital, Sun Yat-sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市天河区天河路600号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
600 Tianhe Road, Tianhe District, Guangzhou |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
赛诺菲(北京)制药有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Sanofi (Beijing) Pharmaceuticals Co., Ltd |
||||||||||||||||||||||
|
研究疾病: |
2型糖尿病 |
||||||||||||||||||||||
|
Target disease: |
Type 2 diabetes mellitus |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
评价实施标准化基础胰岛素治疗路径、针对性基础胰岛素治疗的糖尿病管理培训、以及来自医生同行针对医生日常实践的定期讨论和反馈,对使用基础胰岛素患者血糖控制的改善效果 评价医生对于基础胰岛素治疗的信心 评价医生在基础胰岛素治疗方面日常实践的改变 |
||||||||||||||||||||||
|
Objectives of Study: |
To evaluate the effect of a standardized basal insulin-based treatment pathway supported with dedicated educational training about diabetes care management focusing on basal insulin treatment to Chinese investigators, regular peer to peer discussion and feed-back about the investigator daily practice, on the improvement of glucose control in patients treated by basal insulin. To evaluate health care provider confidence in basal insulin treatment. To evaluate changes in health care provider daily practice regarding basal insulin treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
研究中心: |
||||||||||||||||||||||
|
Inclusion criteria |
Study centers: |
||||||||||||||||||||||
|
排除标准: |
患者:非T2DM(比如1型糖尿病,继发于胰腺疾病、药物或化学制剂所致的糖尿病) |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients: Diabetes other than T2DM (e.g. type 1 diabetes mellitus, diabetes secondary to pancreatic disorders, drug or chemical agent intake) |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 1990-01-01 00:00:00至 To 2017-11-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2015-09-07 00:00:00 至 To 2017-03-05 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
NA |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
NA |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
NA |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |